Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial

BACKGROUND: Belimumab, an anti-B-cell activating factor antibody, is approved for the treatment of auto-antibody positive systemic lupus erythematosus with a high degree of disease activity. Anti-CD20 B cell depletion with rituximab is used in refractory SLE as well, although with variable responses...

Descripción completa

Detalles Bibliográficos
Autores principales: van Schaik, Mieke, Arends, Eline J., Soonawala, Darius, van Ommen, Ellen, de Leeuw, Karina, Limper, Maarten, van Paassen, Pieter, Huizinga, Tom W. J., Toes, René E. M., van Kooten, Cees, Rotmans, Joris I., Rabelink, Ton J., Teng, Y. K. Onno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652788/
https://www.ncbi.nlm.nih.gov/pubmed/36371234
http://dx.doi.org/10.1186/s13063-022-06874-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652788/
https://www.ncbi.nlm.nih.gov/pubmed/36371234
http://dx.doi.org/10.1186/s13063-022-06874-w

Ejemplares similares